BAX - Baxter: Market-Leading Medical Supplier With Lots In The Pipeline
2024-02-21 04:34:18 ET
Summary
- Baxter International gets its buy rating from December reaffirmed, agreeing with today's bullish consensus from SA analysts and Wall Street.
- Positive drivers of the bull call include recent Q4 performance, declining debt, innovative new products in the pipeline, and dividend growth.
- Some weak spots are an unremarkable dividend yield or future revenue growth vs peers, as well as the nature of lengthy FDA approvals on products.
- Downside risks of inflation impacting business costs are on an improvement trend as inflation eases.
An Established Big Pharma Giant
After recently attending a city event hosted by a local cancer foundation, dedicated to cervical cancer patients and survivors, I became inspired to research some recent work by big pharma and came across a company I wrote about in December.
Baxter International ( BAX ) is the company behind drugs like Doxil , which the company says is indicated for treatment of ovarian cancer, particularly those in a progressed or recurred state.
Besides having a portfolio of other medical solutions and products, it also recently launched an IV bag recycling program together with Northwestern Memorial Hospital in Chicago, to reduce IV bag waste and promote recycling. I believe these types of innovative initiatives are another factor that sets this company apart from others....
Baxter: Market-Leading Medical Supplier With Lots In The Pipeline